comparemela.com
Home
Live Updates
Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs : comparemela.com
Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
Beijing BoomRay Pharma has completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Read more here...
Related Keywords
China
,
Tianjin
,
Stockholm
,
Sweden
,
United Kingdom
,
Puhua
,
Shaanxi
,
Beijing
,
Maryland
,
United States
,
Cambridge
,
Cambridgeshire
,
Peking
,
Nanjing
,
Jiangsu
,
Qilu Pharma
,
Stockhom Bioinvent
,
Genor Biopharma
,
Boomray Pharma
,
Cansino Biologics
,
Life Park Venture Fund
,
Research Laboratory
,
Institute Of Biotechnology
,
Ubs Ag
,
Team Of Scientists
,
Academy Of Military Medical Sciences
,
Microbiology Development
,
Scientific Lab For Medicine
,
Vernalis Research
,
Modern Medical Research Laboratory
,
Scientists Working
,
Analysing Biochemicals Samples
,
Scientific Lab
,
Wuxi Apptec
,
Peking University
,
Sequoia Capital China
,
Riverhead Capital
,
Tianfu Sanjiang Asset Management
,
Puhua Capital
,
Shenzhen Jinshen
,
Frontier Biotechnologies
,
Lord Abbett
,
Cellorigin Biotech
,
Jinan Qilu
,
Unison Medicines
,
Chengdu Hitgen
,
Beijing Institute
,
Military Medical
,
China Phase
,
T Cell Engager
,
comparemela.com © 2020. All Rights Reserved.